May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Photodynamic Therapy of Choroidal Neovascularization Using Verteporfin in Pathologic Myopia: Analysis of Visual Outcomes
Author Affiliations & Notes
  • P. Camicione
    Neurology, Ophthalmology,Genetic, University of Genoa, Genoa, Italy
  • D. Ghiglione
    Neurology, Ophthalmology,Genetic, University of Genoa, Genoa, Italy
  • M. Nicolo'
    Neurology, Ophthalmology,Genetic, University of Genoa, Genoa, Italy
  • S. Cicinelli
    Neurology, Ophthalmology,Genetic, University of Genoa, Genoa, Italy
  • S. Barabino
    Neurology, Ophthalmology,Genetic, University of Genoa, Genoa, Italy
  • B. Lantieri
    Neurology, Ophthalmology,Genetic, University of Genoa, Genoa, Italy
  • G. Calabria
    Neurology, Ophthalmology,Genetic, University of Genoa, Genoa, Italy
  • Footnotes
    Commercial Relationships  P. Camicione, None; D. Ghiglione, None; M. Nicolo', None; S. Cicinelli, None; S. Barabino, None; B. Lantieri, None; G. Calabria, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 4908. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. Camicione, D. Ghiglione, M. Nicolo', S. Cicinelli, S. Barabino, B. Lantieri, G. Calabria; Photodynamic Therapy of Choroidal Neovascularization Using Verteporfin in Pathologic Myopia: Analysis of Visual Outcomes . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4908.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To evaluate the visual outcomes of Photodynamic Therapy (PDT) in patients with subfoveal choroidal neovascularization (CNV) in pathologic myopia (PM). Methods:Forty-four patients with subfoveal CNV secondary to PM underwent PDT with verteporfin (Visudyne; Novartis Ophthalmics). The average age was 66.59±15.48 years (range: 29-93 yrs).Twenty-seven were male and seventeen cases were female. ETDRS visual acuity, ophthalmic examinations, color photographs and fluorescein angiography were performed before the first treatment and every three months. The lesion size was measured on fluorescein angiography. At baseline, the mean greatest linear dimension of the entire lesion was 1315.1±809.1 micron (range: 400-5063 micron). Patients were retreated if they had experienced visual deterioration and if angiographic examination demonstrated an active leaking CNV. Results:Mean best- corrected initial visual acuity was 0.23±0.18(range: 0.05-0.76).Follow-up ranged from 9 months to 12 months and 31 of the 44 patients completed the month 9 examination. At the month 9 examination, mean visual acuity was 0.25±0.23 and 8 (25,8%) of the 31 patients lost fewer than eight letters and 13 (41,9%) improved at least five letters (> 1 line ETDRS). Twenty-five of the 44 patients completed the month 12 examination and here final visual acuity remained stable (average:0.27±0.26); seventeen (68%) of 25 patients decreased fewer than eight letters and 10 (40%) improved at least five letters.These patients received a mean of 1.8 treatment. Four of 44 patients had experience a visual loss > 3 ETDRS lines ( >15 letters), during the follow-up period . treatment. Conclusions:Our work confirms that PDT decreases the loss of vision in patients with CNV secondary to PM, as previously partially demonstrated by the Verteporfin in Photodynamic Therapy (VIP) Study. Our conclusions however must be confirmed with longer follow-up and further prospective studies.

Keywords: myopia • choroid: neovascularization • photodynamic therapy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×